Ascendis Pharma A/S expected to post a loss of €1.25 a share - Earnings Preview

Ascendis Pharma A/S

06/08/2025 24:01

Ascendis Pharma A/S ASND.OQ, ASND.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Hellerup Denmark-based   company is expected to report a 293.2% increase in revenue to €141.551 million from €36 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of €1.25 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Ascendis Pharma A/S is $224.50, about 16.9% above its last closing price of $186.59

Previous quarterly performance (using preferred earnings measure in euros). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.49
-1.49
-1.58
Missed
-5.8
Dec. 31 2025
-0.84
-0.96
-0.64
Beat
33.2
Sep. 30 2024
-1.76
-1.74
-1.72
Beat
1.2​
Jun. 30 2024
-1.34
-1.38
-1.91
Missed
-38.1
​​Mar. 31 2024
-1.46
-1.50
-2.30
Missed
-53.1
Dec. 31 2023
-1.98
-2.03
-1.54
Beat
24​
Sep. 30 2023
-2.32
-2.38
-2.88
Missed
-21.1
Jun. 30 2023
-2.57
-2.59
-2.16
Beat
16.6

This summary was machine generated August 5 at 23:01 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)